☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Janssen
Janssen Submits a Marketing Authorisation Application to the EMA for Lazertinib Plus Rybrevant to Treat Lung Cancer
December 23, 2023
PharmaShots Weekly Snapshots (October 09–13, 2023) _
October 14, 2023
Janssen Reports P-IIIb Study (ESCAPE-TRD) Results of Spravato (esketamine nasal spray) for Treatment-Resistant Major Depressive Di...
October 10, 2023
Janssen Reports P-III Study (MARIPOSA) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Non-Small Cell Lung C...
September 29, 2023
Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC...
September 12, 2023
Janssen Reports the MAA Submission of Erdafitinib to the EMA for Locally Advanced or Metastatic Urothelial Cancer with Susceptible...
September 8, 2023
Load more...
Back to Home